ClinicalTrials.gg
CompletedNCT04748926Updated Sep 23, 2025

Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

A Phase 1 interventional study of rilzabrutinib SAR444671 and rilzabrutinib SAR444671 in Healthy Volunteers, sponsored by Principia Biopharma, a Sanofi Company. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Primary Objective:

  • To evaluate the impact of food on the pharmacokinetics (PK) of rilzabrutinib following single oral doses to healthy subjects.
  • To evaluate the impact of formulation on the PK of rilzabrutinib following single oral doses to healthy subjects

Secondary Objective:

- To assess the safety and tolerability of single oral doses of rilzabrutinib administered under fasted and fed conditions

Read the detailed description

The total study duration is approximately 43 days for each participant, including a screening period of 2 to 28 days, treatment period of 12 days, and follow-up of 3 days

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Principia Biopharma, a Sanofi Company is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

First submitted after Principia Biopharma became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants who are overtly healthy as determined by medical evaluation

  • (BMI) within the range ≥18 and ≤31 kg/m2 (inclusive) and a minimum body weight of 45 kg.
  • Female participant is eligible to participate if she is not pregnant or breastfeeding
  • Male participants are eligible to participate if they agree to refrain from donating sperm and use /barrier or be abstinent from intercourse

Exclusion criteria

Exclusion criteria:

  • COVID-19 infection, positive test result for (HIV), virus or virus antibody
  • Use of any prescription or over-the-counter (OTC) medication, herbal products, or dietary supplements within 7 days
  • Participation in another clinical trial of a drug or device whereby the last drug/device administration is within 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.
  • abnormal in vital signs. - Any specific situation during study implementation/course that may rise ethics considerations.

The above information is not intended to contain all considerations relevant to a subject's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive caplets after fast (treatment A) on Day 1 and caplets after meal (treatment B) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.

    Drug: rilzabrutinib SAR444671

  • Experimental
    Group 2

    Participants will receive caplets after meal (treatment B) on Day 1 and caplets after fast (treatment A) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.

    Drug: rilzabrutinib SAR444671

Interventions

  • Drugrilzabrutinib SAR444671

    Pharmaceutical form: caplet Route of administration: oral

  • Drugrilzabrutinib SAR444671

    Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral

  • Drugrilzabrutinib SAR444671

    Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: Cmax

    maximun plasma concentration

    Time frame: From Day 1 to Day 7

  2. Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: Tmax

    time to maximum plasma concentration

    Time frame: From Day 1 to Day 7

  3. Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: AUC0-last

    area under the plasma concentration-time curve from zero to the last measurable concentration

    Time frame: From Day 1 to Day 7

  4. Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: AUC0-inf

    area under the plasma concentration-time curve from zero to infinity

    Time frame: From Day 1 to Day 7

  5. Rilzabrutinib plasma PK parameters following administration of the reference formulation in the fed and fasted states: half-life

    terminal elimination phase half-life

    Time frame: From Day 1 to Day 7

  6. Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: Cmax

    maximun plasma concentration

    Time frame: From Day 11 to Day 12

  7. Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: Tmax

    time to maximum plasma concentration

    Time frame: From Day 11 to Day 12

  8. Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: AUC0-last

    area under the plasma concentration-time curve from zero to the last measurable concentration

    Time frame: From Day 11 to Day 12

  9. Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: AUC0-inf

    area under the plasma concentration-time curve from zero to infinity

    Time frame: From Day 11 to Day 12

  10. Rilzabrutinib plasma PK parameters following administration of two test formulations in the fasted state: half-life

    terminal elimination phase half-life

    Time frame: From Day 11 to Day 12

Secondary outcomes

  1. Treatment-emergent AE and treatment-emergent SAE

    Time frame: Until Day 15

07

Study locations

1 site
  • Investigational Site
    Adelaide, 5000, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in May 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 10, 2021
StartActual
Apr 7, 2021
Primary completionActual
May 21, 2021
CompletionActual
May 21, 2021
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04748926
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Apr 7, 2021
Primary completion
May 21, 2021
Completion
May 21, 2021
Last update
Sep 23, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion